 | • レポートコード：20QY06-07874 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、147ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、糖尿病薬のグローバル市場について種類別（スルホニル尿素、ビグアニド、メグリチニド、チアゾリジンジオン、アルファグルコシダーゼ阻害剤、DPP-4阻害剤、SGLT-2阻害剤）、用途別（診断/クリニック、ICU、在宅医療）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・糖尿病薬市場の概要 ・世界の主要地域別糖尿病薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の糖尿病薬市場規模2015-2026：種類別（スルホニル尿素、ビグアニド、メグリチニド、チアゾリジンジオン、アルファグルコシダーゼ阻害剤、DPP-4阻害剤、SGLT-2阻害剤） ・世界の糖尿病薬市場規模2015-2026：用途別（診断/クリニック、ICU、在宅医療） ・糖尿病薬の北米市場規模2015-2020 ・糖尿病薬のヨーロッパ市場規模2015-2020 ・糖尿病薬の中国市場規模2015-2020 ・糖尿病薬の日本市場規模2015-2020 ・糖尿病薬の東南アジア市場規模2015-2020 ・糖尿病薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Sanofi、Novo Nordisk、MSD、Astrazeneca、Takeda、Novartis、North China Pharmaceutical Group Corporation、Huadong Medicine、Dongbao Pharmaceutical、Hisun Pharmacy、KELUN、Ginwa、Tianan Pharmaceutical、Jumpcan Pharmacy、Guangzhou Baiyun Mountain、SHIJIAZHUANG YILING PHARMACEUTICAL、Wanbang Biopharmaceuticals、Gan & Lee、Taloph） ・糖尿病薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・糖尿病薬の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Diabetes Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Diabetes Drugs market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Diabetes is a condition that keeps your body from making enough insulin. Insulin is a hormone that’s made by an organ called the pancreas. When the body doesn’t make enough insulin, sugar builds up in the blood instead of moving to cells and being used for energy. This causes blood sugar to be high. If blood sugar stays high for a long time, it can cause serious health problems – including blindness, kidney damage, heart disease and stroke. That’s why it’s important to take medicine that helps lower blood sugar levels. Diabetes can be managed so you can live a normal, healthy life.
All diabetes drugs work to lower the levels of sugar in the blood. There are two basic types of diabetes drugs: pills by mouth and shots injected into the skin. More than one drug is often needed to manage diabetes. Some people try different pills, take more than one pill, or take a pill along with shots.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Diabetes Drugs market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Diabetes Drugs industry.
Based on our recent survey, we have several different scenarios about the Diabetes Drugs YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 63620 million in 2019. The market size of Diabetes Drugs will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Diabetes Drugs market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Diabetes Drugs market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Diabetes Drugs market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Diabetes Drugs market. The report also includes nautical information, where it shows Diabetes Drugs market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Diabetes Drugs market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Diabetes Drugs market.
As World overall economic downward trend in the past few years, and international economic situation is complicated, in the next few years there will be many uncertainties, coupled with diabetes drug industry in short supply on the market in the past few years, more companies will enter into the diabetes drug industry, the current demand for diabetes drug product is relatively high; comparing to the ordinary diabetes drug products selling on the market. Diabetes drug’s price remains in the same level as compared with the past years. The signal of market price change indicates the trend in the diabetes drug industry, the market still have large potential.
Geographical Analysis:
Based on region, the global Diabetes Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Diabetes Drugs market are
Sanofi
Novo Nordisk
MSD
Astrazeneca
Takeda
Novartis
North China Pharmaceutical Group Corporation
Huadong Medicine
Dongbao Pharmaceutical
Hisun Pharmacy
KELUN
Ginwa
Tianan Pharmaceutical
Jumpcan Pharmacy
Guangzhou Baiyun Mountain
SHIJIAZHUANG YILING PHARMACEUTICAL
Wanbang Biopharmaceuticals
Gan & Lee
Taloph
Segment by Type
Sulphonylureas
Biguanides
Meglitinides
Thiazolidinediones
Alpha-glucosidase Inhibitors
DPP-4 Inhibitors
SGLT-2 Inhibitors
Segment by Application
Diagnostic/Clinics
ICUs
Home Healthcare
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Diabetes Drugs market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Diabetes Drugs market.
• The market share of the global Diabetes Drugs market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Diabetes Drugs market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Diabetes Drugs market.
1 Diabetes Drugs Market Overview
1.1 Diabetes Drugs Product Scope
1.2 Diabetes Drugs Segment by Type
1.2.1 Global Diabetes Drugs Sales by Type (2020-2026)
1.2.2 Sulphonylureas
1.2.3 Biguanides
1.2.4 Meglitinides
1.2.5 Thiazolidinediones
1.2.6 Alpha-glucosidase Inhibitors
1.2.7 DPP-4 Inhibitors
1.2.8 SGLT-2 Inhibitors
1.3 Diabetes Drugs Segment by Application
1.3.1 Global Diabetes Drugs Sales Comparison by Application (2020-2026)
1.3.2 Diagnostic/Clinics
1.3.3 ICUs
1.3.4 Home Healthcare
1.4 Diabetes Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Diabetes Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Diabetes Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Diabetes Drugs Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Diabetes Drugs Industry Impact
1.5.1 How the Covid-19 is Affecting the Diabetes Drugs Industry
1.5.1.1 Diabetes Drugs Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Diabetes Drugs Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Diabetes Drugs Players to Combat Covid-19 Impact
2 Diabetes Drugs Estimate and Forecast by Region
2.1 Global Diabetes Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Diabetes Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Diabetes Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Diabetes Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Diabetes Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Diabetes Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Diabetes Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Diabetes Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Diabetes Drugs Estimates and Projections (2015-2026)
2.4.3 China Diabetes Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Diabetes Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Diabetes Drugs Estimates and Projections (2015-2026)
2.4.6 India Diabetes Drugs Estimates and Projections (2015-2026)
3 Global Diabetes Drugs Competition Landscape by Players
3.1 Global Top Diabetes Drugs Players by Sales (2015-2020)
3.2 Global Top Diabetes Drugs Players by Revenue (2015-2020)
3.3 Global Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetes Drugs as of 2019)
3.4 Global Diabetes Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Diabetes Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Diabetes Drugs Players (Opinion Leaders)
4 Global Diabetes Drugs Market Size by Type
4.1 Global Diabetes Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Diabetes Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Diabetes Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Diabetes Drugs Price by Type (2014-2020)
4.2 Global Diabetes Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Diabetes Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Diabetes Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Diabetes Drugs Price Forecast by Type (2021-2026)
5 Global Diabetes Drugs Market Size by Application
5.1 Global Diabetes Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Diabetes Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Diabetes Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Diabetes Drugs Price by Application (2015-2020)
5.2 Global Diabetes Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Diabetes Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Diabetes Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Diabetes Drugs Price Forecast by Application (2021-2026)
3 North America Diabetes Drugs Market Facts & Figures
3.2 North America Diabetes Drugs Sales Market Share by Company (2015-2020)
3.3 North America Diabetes Drugs Sales Market Share by Type (2015-2020)
3.4 North America Diabetes Drugs Sales Market Share by Application (2015-2020)
4 Europe Diabetes Drugs Market Facts & Figures
4.2 Europe Diabetes Drugs Sales Market Share by Company (2015-2020)
4.3 Europe Diabetes Drugs Sales Market Share by Type (2015-2020)
4.4 Europe Diabetes Drugs Sales Market Share by Application (2015-2020)
5 China Diabetes Drugs Market Facts & Figures
5.2 China Diabetes Drugs Sales Market Share by Company (2015-2020)
5.3 China Diabetes Drugs Sales Market Share by Type (2015-2020)
5.4 China Diabetes Drugs Sales Market Share by Application (2015-2020)
6 Japan Diabetes Drugs Market Facts & Figures
6.2 Japan Diabetes Drugs Sales Market Share by Company (2015-2020)
6.3 Japan Diabetes Drugs Sales Market Share by Type (2015-2020)
6.4 Japan Diabetes Drugs Sales Market Share by Application (2015-2020)
7 Southeast Asia Diabetes Drugs Market Facts & Figures
7.2 Southeast Asia Diabetes Drugs Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Diabetes Drugs Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Diabetes Drugs Sales Market Share by Application (2015-2020)
8 India Diabetes Drugs Market Facts & Figures
8.2 India Diabetes Drugs Sales Market Share by Company (2015-2020)
8.3 India Diabetes Drugs Sales Market Share by Type (2015-2020)
8.4 India Diabetes Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Diabetes Drugs Business
12.1 Sanofi
12.1.1 Sanofi Diabetes Drugs Corporation Information
12.1.2 Sanofi Diabetes Drugs Business Overview and Total Revenue
12.1.3 Sanofi Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Sanofi Diabetes Drugs Products Offered
12.1.5 Sanofi Recent Development
12.2 Novo Nordisk
12.2.1 Novo Nordisk Diabetes Drugs Corporation Information
12.2.2 Novo Nordisk Diabetes Drugs Business Overview and Total Revenue
12.2.3 Novo Nordisk Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Novo Nordisk Diabetes Drugs Products Offered
12.2.5 Novo Nordisk Recent Development
12.3 MSD
12.3.1 MSD Diabetes Drugs Corporation Information
12.3.2 MSD Diabetes Drugs Business Overview and Total Revenue
12.3.3 MSD Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 MSD Diabetes Drugs Products Offered
12.3.5 MSD Recent Development
12.4 Astrazeneca
12.4.1 Astrazeneca Diabetes Drugs Corporation Information
12.4.2 Astrazeneca Diabetes Drugs Business Overview and Total Revenue
12.4.3 Astrazeneca Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Astrazeneca Diabetes Drugs Products Offered
12.4.5 Astrazeneca Recent Development
12.5 Takeda
12.5.1 Takeda Diabetes Drugs Corporation Information
12.5.2 Takeda Diabetes Drugs Business Overview and Total Revenue
12.5.3 Takeda Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Takeda Diabetes Drugs Products Offered
12.5.5 Takeda Recent Development
12.6 Novartis
12.6.1 Novartis Diabetes Drugs Corporation Information
12.6.2 Novartis Diabetes Drugs Business Overview and Total Revenue
12.6.3 Novartis Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Novartis Diabetes Drugs Products Offered
12.6.5 Novartis Recent Development
12.7 North China Pharmaceutical Group Corporation
12.7.1 North China Pharmaceutical Group Corporation Diabetes Drugs Corporation Information
12.7.2 North China Pharmaceutical Group Corporation Diabetes Drugs Business Overview and Total Revenue
12.7.3 North China Pharmaceutical Group Corporation Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 North China Pharmaceutical Group Corporation Diabetes Drugs Products Offered
12.7.5 North China Pharmaceutical Group Corporation Recent Development
12.8 Huadong Medicine
12.8.1 Huadong Medicine Diabetes Drugs Corporation Information
12.8.2 Huadong Medicine Diabetes Drugs Business Overview and Total Revenue
12.8.3 Huadong Medicine Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Huadong Medicine Diabetes Drugs Products Offered
12.8.5 Huadong Medicine Recent Development
12.9 Dongbao Pharmaceutical
12.9.1 Dongbao Pharmaceutical Diabetes Drugs Corporation Information
12.9.2 Dongbao Pharmaceutical Diabetes Drugs Business Overview and Total Revenue
12.9.3 Dongbao Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Dongbao Pharmaceutical Diabetes Drugs Products Offered
12.9.5 Dongbao Pharmaceutical Recent Development
12.10 Hisun Pharmacy
12.10.1 Hisun Pharmacy Diabetes Drugs Corporation Information
12.10.2 Hisun Pharmacy Diabetes Drugs Business Overview and Total Revenue
12.10.3 Hisun Pharmacy Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Hisun Pharmacy Diabetes Drugs Products Offered
12.10.5 Hisun Pharmacy Recent Development
12.11 KELUN
12.11.1 KELUN Diabetes Drugs Corporation Information
12.11.2 KELUN Diabetes Drugs Business Overview and Total Revenue
12.11.3 KELUN Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 KELUN Diabetes Drugs Products Offered
12.11.5 KELUN Recent Development
12.12 Ginwa
12.12.1 Ginwa Diabetes Drugs Corporation Information
12.12.2 Ginwa Diabetes Drugs Business Overview and Total Revenue
12.12.3 Ginwa Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Ginwa Diabetes Drugs Products Offered
12.12.5 Ginwa Recent Development
12.13 Tianan Pharmaceutical
12.13.1 Tianan Pharmaceutical Diabetes Drugs Corporation Information
12.13.2 Tianan Pharmaceutical Diabetes Drugs Business Overview and Total Revenue
12.13.3 Tianan Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Tianan Pharmaceutical Diabetes Drugs Products Offered
12.13.5 Tianan Pharmaceutical Recent Development
12.14 Jumpcan Pharmacy
12.14.1 Jumpcan Pharmacy Diabetes Drugs Corporation Information
12.14.2 Jumpcan Pharmacy Diabetes Drugs Business Overview and Total Revenue
12.14.3 Jumpcan Pharmacy Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Jumpcan Pharmacy Diabetes Drugs Products Offered
12.14.5 Jumpcan Pharmacy Recent Development
12.15 Guangzhou Baiyun Mountain
12.15.1 Guangzhou Baiyun Mountain Diabetes Drugs Corporation Information
12.15.2 Guangzhou Baiyun Mountain Diabetes Drugs Business Overview and Total Revenue
12.15.3 Guangzhou Baiyun Mountain Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Guangzhou Baiyun Mountain Diabetes Drugs Products Offered
12.15.5 Guangzhou Baiyun Mountain Recent Development
12.16 SHIJIAZHUANG YILING PHARMACEUTICAL
12.16.1 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Corporation Information
12.16.2 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Business Overview and Total Revenue
12.16.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.16.4 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Products Offered
12.16.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
12.17 Wanbang Biopharmaceuticals
12.17.1 Wanbang Biopharmaceuticals Diabetes Drugs Corporation Information
12.17.2 Wanbang Biopharmaceuticals Diabetes Drugs Business Overview and Total Revenue
12.17.3 Wanbang Biopharmaceuticals Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Wanbang Biopharmaceuticals Diabetes Drugs Products Offered
12.17.5 Wanbang Biopharmaceuticals Recent Development
12.18 Gan & Lee
12.18.1 Gan & Lee Diabetes Drugs Corporation Information
12.18.2 Gan & Lee Diabetes Drugs Business Overview and Total Revenue
12.18.3 Gan & Lee Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Gan & Lee Diabetes Drugs Products Offered
12.18.5 Gan & Lee Recent Development
12.19 Taloph
12.19.1 Taloph Diabetes Drugs Corporation Information
12.19.2 Taloph Diabetes Drugs Business Overview and Total Revenue
12.19.3 Taloph Diabetes Drugs Sales, Revenue and Gross Margin (2015-2020)
12.19.4 Taloph Diabetes Drugs Products Offered
12.19.5 Taloph Recent Development
13 Diabetes Drugs Manufacturing Cost Analysis
13.1 Diabetes Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Diabetes Drugs
13.4 Diabetes Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Diabetes Drugs Distributors List
14.3 Diabetes Drugs Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Diabetes Drugs Sales (K MT) Growth Rate by Type (2020-2026)
Table 2. Global Diabetes Drugs Sales (K MT) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Diabetes Drugs Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Diabetes Drugs Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Diabetes Drugs Players to Combat Covid-19 Impact
Table 8. Global Market Diabetes Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Diabetes Drugs Sales (K MT) by Region (2015-2020)
Table 10. Global Diabetes Drugs Sales Market Share by Region (2015-2020)
Table 11. Global Diabetes Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Diabetes Drugs Revenue Share by Region (2015-2020)
Table 13. Global Diabetes Drugs Sales (K MT) Forecast by Region (2021-2026)
Table 14. Global Diabetes Drugs Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Diabetes Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Diabetes Drugs Revenue Share Forecast by Region (2021-2026)
Table 17. Global Diabetes Drugs (K MT) of Key Companies (2015-2020)
Table 18. Global Diabetes Drugs Sales Share by Company (2015-2020)
Table 19. Global Diabetes Drugs Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Diabetes Drugs Revenue Share by Company (2015-2020)
Table 21. Global Diabetes Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetes Drugs as of 2019)
Table 22. Global Diabetes Drugs Average Price (USD/MT) of Key Company (2015-2020)
Table 23. Manufacturers Diabetes Drugs Manufacturing Sites and Area Served
Table 24. Manufacturers Diabetes Drugs Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Diabetes Drugs Players
Table 27. Global Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 28. Global Diabetes Drugs Sales Share by Type (2015-2020)
Table 29. Global Diabetes Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Diabetes Drugs Price (K MT) by Type (2015-2020)
Table 31. Global Diabetes Drugs Sales Share by Type (2021-2026)
Table 32. Global Diabetes Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Diabetes Drugs Revenue Share by Type (2021-2026)
Table 34. Global Diabetes Drugs Price (K MT) by Type (2021-2026)
Table 35. Global Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 36. Global Diabetes Drugs Sales Share by Application (2015-2020)
Table 37. Global Diabetes Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Diabetes Drugs Price (K MT) by Application (2015-2020)
Table 39. Global Diabetes Drugs Sales (K MT) by Application (2021-2026)
Table 40. Global Diabetes Drugs Sales Share by Application (2021-2026)
Table 41. Global Diabetes Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Diabetes Drugs Revenue Share by Application (2021-2026)
Table 43. Global Diabetes Drugs Price (K MT) by Application (2021-2026)
Table 44. United States Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 45. United States Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 46. United States Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 47. United States Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 48. United States Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 49. United States Diabetes Drugs Sales Market Share by Application (2015-2020)
Table 50. Europe Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 51. Europe Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 52. Europe Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 53. Europe Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 54. Europe Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 55. Europe Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 56. China Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 57. China Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 58. China Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 59. China Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 60. China Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 61. China Diabetes Drugs Sales Market Share by Application (2015-2020)
Table 62. Japan Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 63. Japan Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 64. Japan Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 65. Japan Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 66. Japan Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 67. Japan Diabetes Drugs Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 69. Southeast Asia Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 71. Southeast Asia Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 73. Southeast Asia Diabetes Drugs Sales Market Share by Application (2015-2020)
Table 74. India Diabetes Drugs Sales (K MT) by Company (2015-2020)
Table 75. India Diabetes Drugs Sales Market Share by Company (2015-2020)
Table 76. India Diabetes Drugs Sales (K MT) by Type (2015-2020)
Table 77. India Diabetes Drugs Sales Market Share by Type (2015-2020)
Table 78. India Diabetes Drugs Sales (K MT) by Application (2015-2020)
Table 79. India Diabetes Drugs Sales Market Share by Application (2015-2020)
Table 80. Sanofi Corporation Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Sanofi Diabetes Drugs Product
Table 84. Sanofi Recent Development
Table 85. Novo Nordisk Corporation Information
Table 86. Novo Nordisk Description and Business Overview
Table 87. Novo Nordisk Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Novo Nordisk Diabetes Drugs Product
Table 89. Novo Nordisk Recent Development
Table 90. MSD Corporation Information
Table 91. MSD Description and Business Overview
Table 92. MSD Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. MSD Diabetes Drugs Product
Table 94. MSD Recent Development
Table 95. Astrazeneca Corporation Information
Table 96. Astrazeneca Description and Business Overview
Table 97. Astrazeneca Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Astrazeneca Diabetes Drugs Product
Table 99. Astrazeneca Recent Development
Table 100. Takeda Corporation Information
Table 101. Takeda Description and Business Overview
Table 102. Takeda Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Takeda Diabetes Drugs Product
Table 104. Takeda Recent Development
Table 105. Novartis Corporation Information
Table 106. Novartis Description and Business Overview
Table 107. Novartis Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Novartis Diabetes Drugs Product
Table 109. Novartis Recent Development
Table 110. North China Pharmaceutical Group Corporation Corporation Information
Table 111. North China Pharmaceutical Group Corporation Description and Business Overview
Table 112. North China Pharmaceutical Group Corporation Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 113. North China Pharmaceutical Group Corporation Diabetes Drugs Product
Table 114. North China Pharmaceutical Group Corporation Recent Development
Table 115. Huadong Medicine Corporation Information
Table 116. Huadong Medicine Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Huadong Medicine Description and Business Overview
Table 118. Huadong Medicine Diabetes Drugs Product
Table 119. Huadong Medicine Recent Development
Table 120. Dongbao Pharmaceutical Corporation Information
Table 121. Dongbao Pharmaceutical Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Dongbao Pharmaceutical Description and Business Overview
Table 123. Dongbao Pharmaceutical Diabetes Drugs Product
Table 124. Dongbao Pharmaceutical Recent Development
Table 125. Hisun Pharmacy Corporation Information
Table 126. Hisun Pharmacy Description and Business Overview
Table 127. Hisun Pharmacy Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 128. Hisun Pharmacy Diabetes Drugs Product
Table 129. Hisun Pharmacy Recent Development
Table 130. KELUN Corporation Information
Table 131. KELUN Description and Business Overview
Table 132. KELUN Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 133. KELUN Diabetes Drugs Product
Table 134. KELUN Recent Development
Table 135. Ginwa Corporation Information
Table 136. Ginwa Description and Business Overview
Table 137. Ginwa Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 138. Ginwa Diabetes Drugs Product
Table 139. Ginwa Recent Development
Table 140. Tianan Pharmaceutical Corporation Information
Table 141. Tianan Pharmaceutical Description and Business Overview
Table 142. Tianan Pharmaceutical Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 143. Tianan Pharmaceutical Diabetes Drugs Product
Table 144. Tianan Pharmaceutical Recent Development
Table 145. Jumpcan Pharmacy Corporation Information
Table 146. Jumpcan Pharmacy Description and Business Overview
Table 147. Jumpcan Pharmacy Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 148. Jumpcan Pharmacy Diabetes Drugs Product
Table 149. Jumpcan Pharmacy Recent Development
Table 150. Guangzhou Baiyun Mountain Corporation Information
Table 151. Guangzhou Baiyun Mountain Description and Business Overview
Table 152. Guangzhou Baiyun Mountain Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 153. Guangzhou Baiyun Mountain Diabetes Drugs Product
Table 154. Guangzhou Baiyun Mountain Recent Development
Table 155. SHIJIAZHUANG YILING PHARMACEUTICAL Corporation Information
Table 156. SHIJIAZHUANG YILING PHARMACEUTICAL Description and Business Overview
Table 157. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 158. SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Product
Table 159. SHIJIAZHUANG YILING PHARMACEUTICAL Recent Development
Table 160. Wanbang Biopharmaceuticals Corporation Information
Table 161. Wanbang Biopharmaceuticals Description and Business Overview
Table 162. Wanbang Biopharmaceuticals Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 163. Wanbang Biopharmaceuticals Diabetes Drugs Product
Table 164. Wanbang Biopharmaceuticals Recent Development
Table 165. Gan & Lee Corporation Information
Table 166. Gan & Lee Description and Business Overview
Table 167. Gan & Lee Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 168. Gan & Lee Diabetes Drugs Product
Table 169. Gan & Lee Recent Development
Table . Taloph Corporation Information
Table . Taloph Description and Business Overview
Table . Taloph Diabetes Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table . Taloph Diabetes Drugs Product
Table . Taloph Recent Development
Table 175. Production Base and Market Concentration Rate of Raw Material
Table 176. Key Suppliers of Raw Materials
Table 177. Diabetes Drugs Distributors List
Table 178. Diabetes Drugs Customers List
Table 179. Market Key Trends
Table 180. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 181. Key Challenges
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetes Drugs Product Picture
Figure 2. Global Diabetes Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Diabetes Drugs Market Share by Application in 2020 & 2026
Figure 6. Diagnostic/Clinics Examples
Figure 7. ICUs Examples
Figure 8. Home Healthcare Examples
Figure 9. Global Diabetes Drugs Sales (K MT) Growth Rate (2015-2026)
Figure 10. Global Diabetes Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Diabetes Drugs Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 12. Global Diabetes Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Diabetes Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Diabetes Drugs Sales (K MT) Growth Rate (2015-2026)
Figure 16. Europe Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Diabetes Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Diabetes Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Diabetes Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Diabetes Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Diabetes Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Diabetes Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Diabetes Drugs Players Market Share by Revenue in Diabetes Drugs 2015 & 2019
Figure 27. Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Diabetes Drugs Revenue Share by Type (2015-2020)
Figure 29. Global Diabetes Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Diabetes Drugs Revenue Share by Application (2015-2020)
Figure 31. Global Diabetes Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Diabetes Drugs Sales Market Share by Type in 2019
Figure 33. United States Diabetes Drugs Sales Market Share by Type in 2019
Figure 34. Europe Diabetes Drugs Sales Market Share by Company in 2019
Figure 35. Europe Diabetes Drugs Sales Market Share by Type in 2019
Figure 36. Europe Diabetes Drugs Sales Market Share by Application in 2019
Figure 37. China Diabetes Drugs Sales Market Share by Company in 2019
Figure 38. China Diabetes Drugs Sales Market Share by Type in 2019
Figure 39. China Diabetes Drugs Sales Market Share by Application in 2019
Figure 40. Japan Diabetes Drugs Sales Market Share by Company in 2019
Figure 41. Japan Diabetes Drugs Sales Market Share by Type in 2019
Figure 42. Japan Diabetes Drugs Sales Market Share by Application in 2019
Figure 43. Southeast Asia Diabetes Drugs Sales Market Share by Company in 2019
Figure 44. Southeast Asia Diabetes Drugs Sales Market Share by Type in 2019
Figure 45. Southeast Asia Diabetes Drugs Sales Market Share by Application in 2019
Figure 46. India Diabetes Drugs Sales Market Share by Company in 2019
Figure 47. India Diabetes Drugs Sales Market Share by Type in 2019
Figure 48. India Diabetes Drugs Sales Market Share by Application in 2019
Figure 49. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. MSD Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Astrazeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. North China Pharmaceutical Group Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Huadong Medicine Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Dongbao Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Hisun Pharmacy Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. KELUN Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Ginwa Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Tianan Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Jumpcan Pharmacy Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Guangzhou Baiyun Mountain Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. SHIJIAZHUANG YILING PHARMACEUTICAL Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Wanbang Biopharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Gan & Lee Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Taloph Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Key Raw Materials Price Trend
Figure 69. Manufacturing Cost Structure of Diabetes Drugs
Figure 70. Manufacturing Process Analysis of Diabetes Drugs
Figure 71. Diabetes Drugs Industrial Chain Analysis
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles
Figure 74. Porter's Five Forces Analysis
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
リラグルチド薬の世界市場レポート2020 A recently published report by QY Research titled Global Liraglutide Drugs Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate …- 内分泌系薬の世界市場レポート2020 Market Analysis and Insights: Global Endocrine System Drugs Market The global Endocrine System Drugs market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Endocrine System Drugs Scope and Market Size The global…
- 糖尿病デバイスの世界市場レポート2020 Diabetes Devices adopts the method of data collection and analysis of diabetes care for patients with diabetes make reasonable prediction and control of diseases. As living standards improve, an increasing obesity, the equipment has improved people's living habits, disease control effect, is becomin…
- 糖尿病臨床栄養の世界市場レポート2020 A recently published report by QY Research titled Global Diabetes Clinical Nutrition Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides…
- 糖尿病管理の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Diabetes Management market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 12.9% in the forecast period of 2020 to 2025 and will expected to reach USD 8980.2 million by 2025, from USD 5524.5 million in 2019. The Diabetes Manage…